Galectin Therapeutics traded at $1.96 this Friday March 24th, decreasing $0.02 or 1.01 percent since the previous trading session. Looking back, over the last four weeks, Galectin Therapeutics lost 2.00 percent. Over the last 12 months, its price rose by 12.64 percent. Looking ahead, we forecast Galectin Therapeutics to be priced at 1.90 by the end of this quarter and at 1.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
AbbVie 158.02 2.72 1.75% -2.05%
Bristol-Myers Squibb 67.68 0.70 1.05% -7.64%
Galectin Therapeutics 1.96 -0.02 -1.01% 12.64%
Gilead Sciences 80.00 1.24 1.57% 35.80%
Intercept Pharmaceuticals 13.46 -0.23 -1.68% -18.52%
Aceragen Inc 2.26 -0.48 -17.52% -75.07%
Incyte Corp 70.23 -2.03 -2.81% -10.49%
Merck & Co 104.80 0.57 0.55% 28.84%
Regulus Therapeutics 0.95 -0.09 -8.49% 239.89%
Immunic Inc. 1.48 -0.01 -0.67% -87.40%

Indexes Price Day Year
USND 11824 36.56 0.31% -16.55%
US2000 1735 14.63 0.85% -16.51%

Galectin Therapeutics
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.